Clinical Trial

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

Study acronym: SCRIPT-AML
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-07-25; most recent amendment 2024-12-16.
Trial Details
NCT Number NCT05477589
Lead Sponsor Vastra Gotaland Region
Conditions Acute Myeloid Leukemia (AML) in Remission, Stem Cell Transplantation
Enrollment 170 participants
Start Date 2022-06-07
Primary Completion 2029-12-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-19